Management of Hyperglycemia in Diabetic Patients with Hematologic Malignancies During Dexamethasone Therapy

Gosmanov, Aidar R.; Goorha, Salil; Stelts, Sundae; Peng, Limin

doi:10.4158/ep12256.or

Cited by 53 publications

(41 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[4,43] Insulin therapy is the elected treatment. Most patients with glucocorticoids may be managed with a subcutaneous basal bolus insulin regimen, [44] with a starting dosage of 0.3-0.5 IU/kg/day, where 50% of total daily dose is administered as basal insulin and another 50% is administered divided in three doses of nutritional insulin. [4,45] One retrospective study suggests that generally, patients need more insulin to achieve normoglycemia, approximately 0.8 IU/kg/day and proposes give more nutritional insulin: 65-70% versus 30-35% of basal insulin.…”

Section: Journal Of Translational Internal Medicine / Oct-dec 2016 / mentioning

confidence: 99%

Management of hospitalized type 2 diabetes mellitus patients

Marín-Peñalver

Martín-Timón

Cañizo-Gómez

2016

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

Both hyperglycemia and hypoglycemia in hospitalized patients are associated with adverse outcomes including increased rates of infection, longer hospital length of stay, and even death. Clinical trials in patients with type 2 diabetes mellitus proved that by improving glycemic control, we can reduce all of them. Insulin is the preferred treatment for glycemic control in most cases, but alternative treatment options that can normalize blood glucose levels without hypoglycemia are being sought. Moreover, hospitalized patients are particularly vulnerable to severe, prolonged hypoglycemia since they may be unable to sense or respond to the early warning signs and symptoms of low blood glucose. Finally, nutritional support, corticosteroid therapy, and surgery increase the risk of hyperglycemia that leads to an increased risk of morbidity and mortality. We review the management of type 2 diabetes mellitus patients who are admitted to the general medical wards of the hospital for a procedure of intercurrent illness.

show abstract

Section: Journal Of Translational Internal Medicine / Oct-dec 2016 / mentioning

confidence: 99%

Management of hospitalized type 2 diabetes mellitus patients

Marín-Peñalver

Martín-Timón

Cañizo-Gómez

2016

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

show abstract

“…The PET center personnel need to recognize that several commonly prescribed medications can elevate serum glucose levels, including glucocorticoids, phenothiazines, lithium, tricyclic antidepressants, phenytoin, thiazide diuretics, isoniazid, rifampin, and ephedrine (17,18). Notably with glucocorticoids, the PET examination may have to be coordinated either before or after their use or, alternatively, the associated hyperglycemia may need remedial therapy with insulin (19,20). We do not recommend that patients stop taking any of the above medications before their PET scan.…”

Section: Medicationmentioning

confidence: 99%

18F-FDG PET and PET/CT Patient Preparation: A Review of the Literature

Surasi

Bhambhvani

Baldwin

et al. 2014

Journal of Nuclear Medicine Technology

106

View full text Add to dashboard Cite

“…En cuanto al perfil de pacientes incluidos, los estudios que reclutaban sujetos sin y con diabetes previa (una mezcla de pacientes con DIG y DDG) obtenían valores de GM más bajos: Lakhani et al describieron en su estudio, con una prevalencia de DDG del 42%, una GM en el grupo experimental de 170 mg/dl 14 . En cuanto al tipo y la dosis de GC utilizados, las GM son superiores en aquellos estudios, como el de Gosmanov et al, realizados sobre muestras de pacientes con procesos malignos hematológicos que requieren tratamiento con GC potentes de acción prolongada, como es la dexametasona (GM en el grupo asignado a tratamiento basal-bolo de 219 mg/dl) 15 .…”

Section: Discussionunclassified